The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma
Abstract
Purpose: To explore the safety and therapeutic activity of combination anti–B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL). Patients and Methods: Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m 2 and anti-CD20 rituximab 375 mg/m 2 monoclonal antibodies weekly for four doses each. Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]). Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores. Patients with DLBCL had a median of three (range, one to eight) prior regimens (14% resistant to last treatment) and 71% had high intermediate–risk or high-risk International Prognostic Index scores. All patients were rituximab naïve. Results: Treatment was well tolerated, with toxicities principally infusion-related and predominantly grade 1 or 2. Ten (67%) patients with follicular NHL achieved an objective response (OR), including nine of 15 (60%) with complete responses (CRs and unconfirmed CRs). Four of six assessable patients (67%) with DLBCL achieved an OR, including three (50%) CRs. Median time to progression for all indolent NHL patients was 17.8 months. Conclusion: The full-dose combination of epratuzumab with rituximab was well tolerated and had significant clinical activity in NHL, suggesting that this combination should be tested in comparison with single-agent treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Cited by
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
Self-citationThomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9456 · Cited by 416
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Carnahan, J., Stein, R., Qu, Z., Hess, K., Cesano, A., Hansen, H. J., & Goldenberg, D. M. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.05.007 · Cited by 175
Self-citation
Metadata
- Authors
- Leonard, J. P., Coleman, M., Ketas, J., Ashe, M., Fiore, J. M., Furman, R. R., Niesvizky, R., Shore, T., Chadburn, A., Horne, H., Kovacs, J., Ding, C. L., Wegener, W. A., Horak, I. D., & Goldenberg, D. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-01
- Volume
- 23
- Issue
- 22
- Pages
- 5044-5051
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165831472
- Cited by
- 163
- References
- 1
- FWCI
- 15.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2005.13.821
- The paper
- Leonard, J. P., Coleman, M., Ketas, J., Ashe, M., Fiore, J. M., Furman, R. R., Niesvizky, R., Shore, T., Chadburn, A., Horne, H., Kovacs, J., Ding, C. L., Wegener, W. A., Horak, I. D., & Goldenberg, D. M. (2005). Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.13.821
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.